LM
Publicaties op Oncologisch.com
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Re...
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ...
Asciminib versus bosutinib bij CML na ≥2 TKI's: ASCEMBL fase III
Pembrolizumab versus brentuximab vedotin bij recidief/refractair HL: KEYNOTE-204 fase III
Acalabrutinib met of zonder obinutuzumab versus chlorambucil-obinutuzumab bij onbehandelde CLL: ELEVATE-TN fase III
Lenalidomide plus rituximab versus placebo plus rituximab bij recidief indolent NHL: AUGMENT fase III